Shares of Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) fell 17.6% on Friday after an insider sold shares in the company. The stock traded as low as $49.05 and last traded at $54.71. 52,432,171 shares were traded during trading, an increase of 213% from the average session volume of 16,771,090 shares. The stock had previously closed at $66.41.
Specifically, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the sale, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a "hold" rating in a research note on Wednesday, November 6th. Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday. Citigroup cut shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price objective for the company from $24.00 to $25.00 in a research note on Friday, January 10th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price objective for the company from $42.00 to $60.00 in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and an average target price of $28.53.
Check Out Our Latest Stock Report on Hims & Hers Health
Hims & Hers Health Stock Performance
The stock has a 50 day moving average of $35.05 and a two-hundred day moving average of $25.70. The stock has a market cap of $10.73 billion, a PE ratio of 111.58 and a beta of 1.35.
Hedge Funds Weigh In On Hims & Hers Health
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC grew its stake in Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after acquiring an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC grew its stake in Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock valued at $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. Finally, State Street Corp grew its stake in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company's stock valued at $85,221,000 after acquiring an additional 206,078 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
See Also
Before you consider Hims & Hers Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims & Hers Health wasn't on the list.
While Hims & Hers Health currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
